Novonesis (Novozymes) B
NSISBC.XD
CBOE Europe428.30
DKK
+13.20
- -
Novonesis (Novozymes) B
NSISBC.XD
(CBOE Europe)
Recent
price
428.30
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Novonesis (Novozymes) B operates as a global biosolutions company focused on the research, development, production, and sale of industrial enzymes, microorganisms, functional proteins, and biopharmaceutical ingredients; its core offerings span enzymes for food and beverage fermentation including dairy cultures and anti-staling agents for baked goods, probiotics and Human Milk Oligosaccharides for human health and infant nutrition, feed enzymes and microbial solutions for animal health and nutrition, solutions for household care and industrial cleaning such as laundry and dishwash detergents, crop nutrition and soil health products for agriculture, and advanced yeasts and enzymes for bioenergy and renewable fuels. The company serves more than 30 industries worldwide including food and beverages, household care, agriculture, animal nutrition, bioenergy, technical applications, pharmaceuticals, and human health, with customers ranging from consumer goods manufacturers to agricultural producers and pharmaceutical firms. Founded through the 2024 merger of Novozymes—established in 2000 as a spinout from Novo Nordisk with roots tracing to 1925—and Chr. Hansen, Novonesis maintains its headquarters in Lyngby, Denmark, and conducts operations across Europe, North America, Asia Pacific including major facilities in China, India, and Japan, Latin America encompassing Brazil and Argentina, and other regions such as the United States and United Kingdom. In a significant recent development, Novonesis completed in June 2025 its acquisition of dsm-firmenich's share in their longstanding Feed Enzymes Alliance for approximately EUR 1.5 billion, fully integrating sales, distribution, research, development, and production capabilities to expand its animal biosolutions portfolio, enhance market reach with a combined enzymes and probiotics offering, and achieve low-single-digit revenue accretion while maintaining strategic supply relationships. This transaction, announced in February 2025, bolsters Novonesis's leadership in planetary health solutions amid ongoing portfolio refinements including plans to explore exits from certain animal nutrition segments. Class B shares trade under the ticker NSISBC.XD on Nasdaq Copenhagen.